Sunitcap 12.5mg Capsule (Sunitinib)

Sunitcap 12.5mg Capsule contains sunitinib, an oral multi-target receptor tyrosine kinase inhibitor. It blocks signalling pathways including VEGFR and PDGFR that contribute to tumour growth and angiogenesis. Sunitinib 12.5mg Capsule is used in selected patients with gastrointestinal stromal tumour (GIST), advanced renal cell carcinoma and pancreatic neuroendocrine tumours, depending on the disease setting and approved label. Treatment schedules vary by indication and may involve treatment cycles or continuous daily dosing. Because sunitinib capsule can affect blood pressure, heart function, thyroid function, liver, blood counts and other organs, regular monitoring is required. Sunitcap 12.5mg Capsule is a prescription medicine and dose changes should only be made by the treating oncologist.

For current Sunitcap 12.5mg Capsule availability, in the present day, a licensed pharmacy or authorized oncology medication supplier in India could be consulted. Availability of the medication must be established before ordering, and its use must be on the recommendation of the oncologist alone.​

Sunitinib 12.5mg Capsule is used for GIST after disease progression on or intolerance to imatinib; for advanced or metastatic renal cell carcinoma; and for progressive, well-differentiated pancreatic neuroendocrine tumours in selected patients with unresectable locally advanced or metastatic disease. Approved indications and dosing schedules vary by jurisdiction. Treatment choice considers previous therapy, tumour biology, cardiovascular health, liver function, thyroid function and potential interactions.

Sunitinib Capsule inhibits several receptor tyrosine kinases, including VEGFRs, PDGFRs, KIT, FLT3 and RET. These pathways are involved in tumour proliferation and angiogenesis. In GIST, inhibition of KIT/PDGFR signalling is especially relevant; in renal cell carcinoma and pancreatic neuroendocrine tumours, anti-angiogenic effects are important. Its broad kinase activity also explains the need to monitor blood pressure, cardiac function, thyroid function, liver tests and blood counts.

Evidence context: The studies below are pivotal or widely cited evidence supporting the sunitinib 12.5mg Capsule in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Sunitcap 12.5mg Capsule may cause side effects, and their frequency varies by indication, dose, combination regimen and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

For GIST after imatinib failure/intolerance and for advanced renal cell carcinoma, a common labelled regimen is 50 mg orally once daily for 4 weeks followed by 2 weeks off treatment (Schedule 4/2). For pancreatic neuroendocrine tumours, the labelled regimen is 37.5 mg orally once daily continuously. Dose adjustments are made in 12.5mg steps depending on toxicity and interactions. The 12.5 mg capsule is commonly a dose-adjustment strength, not the usual starting dose for most indications.

Administration guidance: Take Sunitcap 12.5mg Capsule exactly according to the schedule prescribed for your condition. Sunitinib 12.5mg Capsule may be given in cycles, such as 4 weeks on treatment followed by 2 weeks off, or as continuous daily dosing in some indications. It can generally be taken with or without food. Swallow the capsule whole and take it at approximately the same time each day. Avoid grapefruit products. Blood pressure, blood counts, liver function, thyroid function and cardiac status may be monitored. Dose interruption or reduction may be required for significant toxicity. Never alter the cycle or dose without your oncologist.​

If a dose is missed, do not double the next dose. Resume the normal schedule unless the oncology team instructs otherwise. Do not repeat a dose after vomiting.

Monitor blood pressure, CBC, liver function and thyroid function. Assess cardiac function in patients with risk factors and consider ECG/electrolyte monitoring for QT risk. Monitor for bleeding, proteinuria and signs of thrombotic microangiopathy. Dental assessment may be appropriate before treatment in high-risk patients.
Practical monitoring checklist
• Blood pressure before treatment and regularly during therapy
• Liver function according to baseline risk and treatment label
• Renal function and hydration/renal toxicity assessment as clinically indicated
• Cardiac assessment/ECG or ejection-fraction monitoring when clinically indicated

1. FDA/EMA Sutent (sunitinib capsule) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021938s019s020lbl.pdf
2. NCCN Clinical Practice Guidelines for Kidney Cancer and GIST. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440
3. National Library of medicine. Sunitinib: ten years of successful clinical trails.https://pmc.ncbi.nlm.nih.gov/articles/PMC5313263/.
4.ScienceDirect. Sunitinib 12.5mg Capsule. Https://pmc.ncbi.nlm.nih.gov/articles/PMC5313263/.
5. Frontiers. Sunitinib. Https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1294688/full